Posts

The convergence of AI with pharma marketing can lead to more efficient campaigns, better customer relations, and a deeper understanding of market trends and behaviors.  As relates to AI in the biopharma industry, Jay Appel, chief digital and growth officer at The Bloc talks about what has him most excited.

The company’s new campaign, “Countdown at a Crossroads” featuring TV host Sherri Shepherd, shines a spotlight on how CGM technology can help people living with diabetes improve health outcomes and have a better quality of life.

As the COVID-19 pandemic continues to recede, the top pharma companies intensified their focus into areas such as cancer and metabolic diseases to build up their pipelines, and their growth prospects, for the future.

The Medical Advertising Hall of Fame honored 2019 inductees Carol DiSanto and Charlene Prounis on Feb. 7th at The Pierre in New York City.

The threatened “pharma marketing tax” may be back in play during 2019, at both the federal and state levels.

The U.S. Department of Health and Human Services (HHS) is considering proposing a plan that has many moving parts, one of which could potentially take the price that Medicare pays out to providers for Medicare Part B drugs and turn it on its head.

The talent and tenacity of immigrants can help drive the life sciences industry into the future, if we have the will and the wisdom to encourage it.

In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.

Prices, profits and promotional spend are closely linked. Reduce prices and promotion will plummet. But wait, the Republicans are in control. Accordingly, pharma, its marketing partners and even Wall Street often rest easy, especially when Republicans control Congress and the White House.

Emboldened by 2017’s back-to-back FDA approvals of the first drugs that use genetically engineered patient immune cells – Kymriah (tisagenlecleucel) to treat leukemia and Yescarta (axicabtagene ciloleucel) to combat large-B-cell lymphomas – immunotherapy researchers are continuing to revolutionizing cancer treatment. But uneven patient response rates and the side effects often associated with immunotherapies are putting high priority on accurately identifying which patients would benefit most from particular treatment options.